Exhibit 99.1
Apr 2022 1
I N V E S T M E N T O V E R V I E W LEGAL D I S C L A I M E R T H I S DO C U M E N T H A S B EE N P R E P A R E D F O R I N F O R M A T I O N AL P U R P O S E S O N L Y . This document contains summary information about Brain Scientific Inc. (“Brain Scientific”). It does not purport to be complete, and no representations or warranties about such information are made by Brain Scientific or its representatives. This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities of Brain Scientific. Any such offer will be made only pursuant to an effective registration statement or an exemption from registration. This document contains forward - looking statements relating to future events or the future financial performance and operations of Brain Scientific. 2 Forward - looking statements, which involve assumptions and describe Brain Scientific’s intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by the use of the words “may,” “could,” “should,” “will,” “would,” “expect,” “anticipate,” “plan,” “potential,” “estimate,” “believe,” “intend,” “project,” “forecast,” the negative of such words and other variations on such words or similar terminology. These forward - looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Brain Scientific’s public filings with the Securities and Exchange Commission, such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Brain Scientific and its securities. In light of these risks, uncertainties and assumptions, the forward - looking events discussed in this document might not occur. Brain Scientific is not obligated to publicly update or revise any forward - looking statements, whether as a result of new information, future events or otherwise. No independent party has audited the forecasts, if any, set forth herein, nor has any independent party undertaken to confirm that any hypothetical performance or other performance that may be set forth herein adheres to the assumptions or conditions specified herein.
Why BRSF? Unique, Disruptive T e c hn o l og y : (FDA - Cleared and Patented) H u ge M a r ke t Potential Software S u b s c ri pt i on Sales Medical Device Sales E xp e ri e nc e d Team 3
A MedTech Company T h e c o m p a n i e s i n ves ted $ 2 3 M + i n d e v e l o p i n g , r e f i n i n g a n d p a t e n t i n g t h e technologies B r a i n S c i e n ti f i c w a s fo u n de d by r e s e a rc h e r s a n d ca r ee r scientists BREAKTHROUGH D i s r u p t i v e m e d i c a l d e v i c e s a n d a n eu r o l og y S aa S p l a t for m M a r ke t s t r a t e g y de f i n e d, s a l e s a n d m a r k e t i n g t e a m s o n b oa r d , d e m a n d s u r g e fr o m market Gr o w i n g p i p e li n e a n d s cali n g manufacturing P r o ve n m a n a ge me nt t e a m j o i n s t o s c a l e r even u e a n d operations COMMERCIALIZATION Me d T e c h p l a t f o r m c o m p a n y D i sr u p t i v e t e c h n o l o g y in g r o w i ng m a r k e t s Pu b li c c o m p a n y ( O T C : B R S F ) u p - li s ti n g t o NA S DA Q i n 2 0 22 O P P O R T U N I T Y 4
Intellectual Property 15 US P a t e n t s 25 W o r l d P a t e n ts 7 T r a d e S e c r e t s 2 F D A C le a r e d P r o d u c t s ( 5 1 0 k ) 5
W e a r e s e lli n g i n t o t h e large, growing neurology market with a n i nn o v a t i v e p l a t f o r m of p r o d u c t s Ou r di s r u p t i v e so l ut i o n s a r e p o i s e d t o q u i c k l y e x p a n d i n t h e s e markets Total Addressable Market Sources: Industry and Research Reports, Our Research & Analysis $1.0B 6 $1.09B $ 1 . 1 9 B $1.3B $1.41B $ 1 . 5 4 B $1.83B $1.68B 2 0 2 1 2 0 2 2 2 0 2 3 2 0 2 4 2 0 2 5 2 0 2 6 2 0 2 7 2 0 28
Apr 2022 Neurology Products 7
A Pressing Need • Ne u r o l o g i s t s a r e i n v e r y s h o r t su p p l y , w it h 3 0 % o f pediatric neurology clinics experiencing new pa t i e n t w a i t t i m e s o f 1 6 w ee k s o r l o n ge r • Existing EEG systems are costly, wired, and consume too much space • CD C r e p o r ts 1 . 6 t o 3 . 8 m illi o n c o n c u ss i o n s o c cu r i n t h e U S ea c h y e a r ; 2 i n 1 0 h ig h s c h oo l c o n t a c t s p o r t athletes get concussions in any given year 8
H O M E AMBULATORY ER ICU Market Pain Points O n l y 3 0 % o f U S hospitals have equipment for routine EEGs due to cost and space. S pe c i a li z e d E E G t ec h n i c i a n s a r e r e q u i r e d t o a d m i n i s t e r t h e t ec h no l o g y a n d r e a d t h e d a t a . Bulky equipment restricts the universality a n d acc e ss i b ili t y o f t h e technology. There are neurology deserts = acute neurologists shortfall. Twenty states have less than ten neurologists per 10,000 patients. X X X O n l y 4 5 % o ff e r EE G Monitoring EEG i s m o s t l y u n a v a i l ab l e d u r i n g a p a t i e n t ’ s j o u r n e y
Our Solution TH E RE S UL T S A disposable and easy - to - apply clinical - grade NeuroCap A p o r t a b l e a n d w i r e l e s s EEG amplifier A s ec u r e c l o u d f o r d a t a t r a ns f er a n d s t o r ag e An AI - powered a n a l y s i s p l at f o r m A teleneurology n e t w o r k o f p r o vi d e r s All hospitals can efficiently perform EEG Tests Technicians can upload test data to the cloud Neurologists can provide diagnoses remotely
N e u r o C ap 11 • Our NeuroCap is disposable , eliminating co n t a m i n a t i o n ; F a s t e r a n d eas i er t o a pp l y – r e s u l t i n g in more accurate EEG readings • The NeuroCap is perfect for giving EEG tests when neurology technicians aren’t available • E p il e p s y m o n i t o r i n g , c o n c u ss i o n s , m i g r a i n e s , a n d o t h e r l a r g e - s c a l e u s e c a s e s c o u l d b e n e f i t f r o m u s i n g o u r c a p s i n t h e f i e l d o r v i a te l e m e d i c i n e • The NeuroCap competes on mobility, disposability, con v e n i e nc e , e ff i ci e n cy • Our device provides measurements – no diagnostics o r i n te r p r et a t i o n s p r o v i d e d o u t s i d e o f a n e u r o l o g i s t ’ s review
N e u r o E E G • Our NeuroEEG is small, wireless, portable EEG amplifier that records data from our NeuroCap and up l o ad s i t t o a HI PA A C om pli a n t pr opr i e t a r y c lo u d platform • T h e N e u r o EE G i s m uc h m o r e c o n v e n i e n t f o r pa t i e n t s and neurologists, especially in telemedicine or field settings to allow remote monitoring of EEG results • T h e cl o u d p l a t fo r m be h i n d t h e N e u r o EE G wi ll be leveraged to create a large base of secured neurology data, predictive AI, and additional services • T h e N e u r o EE G r e i n f o r c e s t h e N e u r o C a p ’ s st r e n g th s o f mo b ili t y , con v e n i e nc e , a n d e ff i ci e n cy w h e n u s e d together 12
Neurology SaaS Platform • Collect, monitor, aggregate, analyze, and report data from NeuroCap, NeuroEEG, and additional devices and market sources (data banks, researchers, etc.). Sophisticated ML algorithms. • White - labeled Physician and Patient portal, integrating into Electronic Medical Records (EMRs) and other medical record databases. • Network of Physicians and experts to facilitate collaborative diagnosis, analysis, and research to perform: • EE G d a t a o v e r l a y a n a l y s i s ( s t u d y c o m p o s i t i o n / ele c t r i c al changes over time due to TBI or Neurological disorders) • Pharmacology studies (before, during, after administration) • Neurological disorders (Seizure, Sleep, Tumors, Infection/ I n j u r y ( T B I ) , D e m e n t i a , S t r o k e ) • S t r u c t u r a l I n j u r y C l a ss i f ie r ( S I C ) , B r a i n F u n c t i o n I n d e x ( BF I ) , a n d C o n c u ss i o n I n d e x ( C I ) • Neurocognitive Assessments (Attention, behavioral, developmental) P a t i en t s V i e w Pr o f il e Sc hedu l e A p po i n tm en t 13
A L Z H E I M E R ’ S DISEASE Global Market Demand 264 MILLION DE P R E SS I O N 13 M I LL I O N S T R O K E MILLION EPILEPSY 50 MILLION ADHD IN C H I L D R E N 12 9 MIGRAINE M I L L I O N 30 DEMENTIA MILLION 50 SLEEP DISORDERS 20 - 45% A D U L T P O P . 24 69 MILLION MILLION TRAMATIC BRAIN INJURY 14
• Massive greenfield market opportunities • Aging population in need of more diagnostics • Wearables becoming widely adopted for monitoring • Neuro - telemedicine opening new untapped markets Untapped Markets M o b il e C l i n i c s Athletics De p a r t m e n t s N u r s i n g Homes Pain M an a g e m e n t Clinics S l ee p L a b s 15
Apr 2022 Motion Products 16
LINEAR MOTORS O u r li n e a r a n d m i n i li n e a r m o t o r s c a n b e u s e d t o ma ke a n i n c is io n sm a ll e r t h a n t h e human hair . ROTARY MOTORS O u r r o t a r y a n d m i n i r o t a r y m o t o r s c a n b e u s e d t o p r e c i s e l y d i s p e n s e pr e s c r i p t i o n d r u g s ov e r a l o ng p e r i o d o f t i m e f r o m a s m a ll battery. M a r ke t O pp o r t u n i t y: • Medical devices require high precision, which t r a d i ti o n a l m o t o r s l a c k . O t h e r m o t o r s a l s o require a consistent energy source to hold position, which drains wearable batteries • Traditional motors are heavy and slow, which are inefficient for ER and ambulatory services P r o d uc t F e a t u r e s & B e n e f i t s : • Up t o 1 000 x m o r e p r e c i se a n d 1 00 x fa s t e r response than direct competitor (DC Motors) • Z e r o e n e r g y t o h o l d p o s i ti o n • 50 - 7 5 % le s s w ei g h t t h a n c o m p e ti t o r s • Z e r o ele c t r o m a g netic i s s u e s Motion Products 17
D C T e c h n o l o g y $140 • Li m i t e d p r e c i s i o n • Co m p l e x c o n t rol • H e a vy m a t e r i a l s • M an y p a r t s • H i g h p r e c i s i o n • So p h i s t i c at e d c o n t r o l s • H e a v y m at e r i a l s • C o m p le x p a r t s Co n v e n t i o n a l P i e z o $1,200 Ou r I nn o v a t i v e MO T I O N T E C H N O L O G Y $120 • Precise • S i mp l e t o c o n t r o l • L i g h t w e i g h t m at e r i a l s • F e w p a r t s Motion Products 18
19 Hi g h p r e ci s i o n , f a s t r e s p o n s e a n d h i g h s p ee d m ak e o u r li n e a r m o t o r s a n i m p r o v e d s ol u t i o n f o r a u t o m a t e d m i c r o s c o p e s t a ge s . In a u t o m a t e d s t e p , s c a n sy s t e m s f o r a n a l y s i s o f l a r g e a r e a , o r m u lt i p la t e s a m p l e s , t h i s e n a b l e s t h r o u g h p u t a n d pro d u c t i v i t y t o be g r e a t l y improved. M I C R O S C O P E S T A G E S M I C R O D O S I NG P U MP F l u i d de li v e r y s y r i n g e p u m ps ca n b e n e fi t f r o m o u r p o w e r de n s e a n d p r e c i s e d i r e c t d r i v e p i e z o t e c hn o l o g y . D i r e c t d r i v e r e d u c e s c o m p le x i t y . H i g h e r p r e c i s i o n e n a b le s u s e o f h i gh e r c o n c e n t r a t i o n s ol u t i o n s h e n c e e x t e n d i n g u se c y c l e s a n d r e d uc i ng downtime. O u r p r e c i s e , h i g h - sp ee d a n d fast response motion products a r e w e ll - s u i t e d t o t h e r e q u i r e m e n t s f o r i n c re a s i ng n u mb e r s o f e l e c t r o n i c a u t o i n j e c t o r s a n d j e t i n j e c t o r s . M o r e t r e a t m e n t s a r e be i ng en a b l ed f o r w e a r a b l e d r u g t r e a t m e n t a s w e ll . R O B O T I C S U RG E RY Target Devices
O u r m o t o r s c a n o pe r a t e i n h i gh m a gn e t i c f i e l d s a nd pro v i de m o t i v e p o w e r fo r de v i c e s s uc h i n f u s i o n p u m ps a n d v e n t ila t o r s w h e r e e l e c t r o m a g n e t i c d ev i c es a r e i m p o ss i b l e t o u s e . IN F U S I O N M R I P U M P S WE A R A B L E D I S P E N S E R S O u r m o t o r s o f f e r p o w e r de n s e , li g h t w e i g h t a n d e f f i c i e n t m o tio n w i t h d i r e c t d r i v e e n a b li n g t h e de s i g n o f s m a l l a n d c o m p a c t dru g de li v e r y s y s t e m s . In c r e a s i ng n u mb e r s o f t r e a t m e n t s a r e b e i n g e n a b l e d f o r w e a r a b l e d r u g t r e a t m e n t . Inf u s i o n a nd s y r i nge p u mp s a r e w i d e l y u s e d f o r c o n t i n u o u s dru g de li v e r y . O u r d i r e c t d r i v e p i e z o m o t i o n c a n i m p r o v e p r e c i s i o n o f de li v e r y e n a b l i ng sm a ll e r d o se s u s i n g h i g h e r c o n c e n t r a t i o n d r u g s a n d r e d uc i n g t h e n u m b e r o f r e f i ll s a n d p a t i e n t d i s r u p tio n . S Y R I N G E P U M P S Target Devices 20
Apr 2022 Organization 21
Hassan Kotob C H A I R M A N & CEO 22 29 y e a r s o f e x p e r i e n c e b r i ng i ng i nn o v a t i v e t e c hn o l o g i e s t o t h e m a r k e t , g r o w i n g b u s i n e ss e s , and creating significant shareholder value F ou n d e r a n d C E O o f N o r t h P l a i n s , a s o f t w a r e s ol u t i o n t h a t p i o n ee r e d t h e m a r ke t f o r e n t e r p r i s e digital asset management; sold to top private equity firm P r e s i d e n t o f C T e x t , a c o m p a n y t h a t r e v o l ut i o n i z e d the publishing industry; sold to a strategic buyer P r e s i d e n t a n d C E O o f M e d a s y s / D i g i t a l D e s i g n Systems, a first mover in PACS and telemedicine ; Initial Public Offering
BRSF Leadership Team Bonnie - Jeanne Gerety | CFO Bonnie - Jeanne brings over 35 years of financial and consulting experience within the technology industry. She joined Piezo Motion in early 2020 as the CFO. Prior to that, she was the CFO of North Plains, LLC from 2014 through 2019. Her previous experience was as a Managing Director at Protivti, responsible for the Atlanta and Raleigh offices from 2004 to 2014. Prior to Protiviti, she was a Managing Director at BearingPoint from 2002 to 2004 and a Partner in the consulting division of Arthur Andersen, LLP specializing in technology, media and communications industries from 1986 to 2002. Fred Anthony | CTO Fred brings a proven track record of success and over 25 years of experience, innovation, and achievement in various technology industries. Mr. Anthony started his career in 1998 as a founder of Triforce Technologies Inc., a private technology consulting and services company servicing the B2B sector. From late 2019 to 2021, he was CTO at Luxury Presence, a silicon - valley company with an all - in - one platform for real estate agents. From 2019 to 2020, he served as Executive Director of Engineering at Bolt Mobility. From 2016 to 2019, he served as CTO at North Plains Systems. From 2014 to 2016, he served as CTO at CreativeDrive. CONFIDENTIAL MATERIALS 23
BRSF Leadership Team Fe li c i a M aher | V P o f S a l e s – M ed i ca l P r oduc t s Felicia brings extensive revenue management experience and over 17 years of launching, marketing and growing sales for high - tech devices and platforms in the medical field. She has held various positions including Director of Sales at A&D Engineering, where she managed relationships including the Veteran’s Affairs and Department of Defense, as well as Senior Regional Sales Manager at Medtronic, a leading medical device manufacturer. She has both domestic and international sales experience in the medical device market and will leverage her full experience and network to rapidly scale our medical product sales. CONFIDENTIAL MATERIALS 24 T odd Be r t r and | V P o f S a l e s – M o ti o n P r oduc t s Todd brings a successful background generating business in technology industries to our team. Todd has been in sales management for over 20 years, including at Emerson Industrial Automation and A&D Engineering, where he previously met and worked with Felicia. He has experience growing sales for technologies across the value chain, from drives and motion control systems to finished machines and system/process sales. Todd likewise has both international and US experience, having been responsible for sales across Canada, the US, and LATAM in prior positions. At Piezo Motion, he has already signed more than 15 distributors as well as collaborated directly with customers to meet their specific needs across off - the - shelf orders and custom projects.
BRSF Organization Exe c u t i v e T e a m a n d O v e rs i g h t - CE O , C F O , CT O 25 Motion P i e z o M o t i o n - R & D a n d P r o d u c t E n g i n ee r i n g - P r o d u c t D e s i g n & I nn o v a t i o n - S a l e s S h a r ed Se r v i c es - M a nu f a c t u r i n g & Q A - M a r k et i n g & I R - En g i n ee r i n g & I T - F i n a n c e & A d m i n - Compliance/Legal Neurology B r a i n S c i e n t i f i c - R & D a n d P r o d uc t E n g i n ee r i n g - P r o d uc t D e si g n & I nn o v a t i o n - S a l e s
Contact Information Email: i r @ b r a in s c ien t ifi c . c om Website: https://ir.brainscientific.com/ LinkedIn: https:// www.linkedin.com/company/brainscientific 26
Apr 2022 Thank You 27